4.375

4.06% 0.185

Iovance Biotherapeutics Inc (IOVA)

Overview News Price History Option Chain Financials Why IOVA Down? Discussions Forecast Stock Split

Iovance Biotherapeutics Inc stock is traded at $4.375, with a volume of 8.60M. It is up +4.06% in the last 24 hours and up +3.07% over the past month. Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

Previous Close:

$4.19

Open:

$4.25

24h Volume:

8.60M

Relative Volume:

0.58

Market Cap:

$1.96B

Revenue:

$285.55M

Net Income/Loss:

$-353.86M

P/E Ratio:

-4.6048

EPS:

-0.9501

Net Cash Flow:

$-305.02M

1W Performance:

+4.81%

1M Performance:

+3.07%

6M Performance:

+57.40%

1Y Performance:

+156.47%

1-Day Range:

$4.07

$4.41

1-Week Range:

$3.85

$4.5399

52-Week Range:

$1.69

$5.63

Iovance Biotherapeutics Inc Stock (IOVA) Company Profile

Name

Iovance Biotherapeutics Inc

Sector

Healthcare (1100)

Industry

Biotechnology (615)

Phone

(650) 260-7120

Address

825 INDUSTRIAL ROAD, SAN CARLOS

Employee

975

Twitter

Next Earnings Date

2026-08-06

Latest SEC Filings

IOVA's Discussions on Twitter

Compare IOVA vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
IOVA Iovance Biotherapeutics Inc	4.3799	1.87B	285.55M	-353.86M	-305.02M	-0.9501
VRTX Vertex Pharmaceuticals Inc	523.84	134.41B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	672.80	68.13B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	918.50	57.01B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	321.00	41.79B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	190.39	40.39B	742.00K	-1.37B	-1.07B	-7.0731

Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-25-26	Upgrade	Citizens	Mkt Perform → Mkt Outperform
Jul-15-25	Downgrade	Goldman	Neutral → Sell
May-16-25	Downgrade	UBS	Buy → Neutral
May-12-25	Downgrade	Truist	Buy → Hold
May-09-25	Downgrade	Citizens JMP	Mkt Outperform → Mkt Perform
Oct-24-24	Initiated	UBS	Buy
Jul-29-24	Downgrade	Piper Sandler	Overweight → Neutral
Nov-20-23	Initiated	Goldman	Buy
Sep-18-23	Reiterated	Barclays	Overweight
May-30-23	Upgrade	Wells Fargo	Equal Weight → Overweight
Mar-27-23	Resumed	Wells Fargo	Equal Weight
Jan-27-23	Upgrade	Piper Sandler	Neutral → Overweight
Dec-09-22	Downgrade	Goldman	Buy → Neutral
Oct-31-22	Initiated	Guggenheim	Neutral
Aug-18-22	Resumed	Wells Fargo	Equal Weight
Jan-28-22	Upgrade	Stifel	Hold → Buy
Dec-07-21	Resumed	Cowen	Outperform
Jun-10-21	Upgrade	JMP Securities	Mkt Perform → Mkt Outperform
May-20-21	Downgrade	Piper Sandler	Overweight → Neutral
May-19-21	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
May-19-21	Downgrade	Stifel	Buy → Hold
May-03-21	Initiated	Truist	Buy
Apr-16-21	Initiated	Goldman	Buy
Mar-08-21	Upgrade	H.C. Wainwright	Neutral → Buy
Dec-15-20	Downgrade	H.C. Wainwright	Buy → Neutral
Oct-06-20	Downgrade	Wells Fargo	Overweight → Equal Weight
Apr-22-20	Initiated	Mizuho	Buy
Mar-04-20	Initiated	Barclays	Overweight
Feb-26-20	Reiterated	H.C. Wainwright	Buy
Feb-26-20	Reiterated	Oppenheimer	Outperform
Dec-18-19	Initiated	JMP Securities	Mkt Outperform
Oct-01-19	Initiated	Stifel	Buy
Apr-29-19	Initiated	Piper Jaffray	Overweight
Feb-28-19	Reiterated	Chardan Capital Markets	Buy
Feb-07-19	Initiated	Robert W. Baird	Outperform
Dec-31-18	Resumed	B. Riley FBR	Buy
Jul-06-18	Reiterated	Chardan Capital Markets	Buy
Apr-10-18	Upgrade	B. Riley FBR, Inc.	Neutral → Buy
Mar-13-18	Reiterated	B. Riley FBR, Inc.	Neutral
Feb-23-18	Downgrade	B. Riley FBR, Inc.	Buy → Neutral
Jan-25-18	Reiterated	H.C. Wainwright	Buy
Nov-01-17	Reiterated	B. Riley FBR, Inc.	Buy

View All

Iovance Biotherapeutics Inc Stock (IOVA) Latest News

Jul 05, 2026

IOVAIovance Biotherapeutics Inc Options - Finviz

Jul 05, 2026

Jul 04, 2026

Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - Yahoo Finance

Jul 04, 2026

Jul 02, 2026

Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance - TradingView

Jul 02, 2026

Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028 - Stock Titan

Jul 02, 2026

IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits

Jul 02, 2026

Jun 30, 2026

IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits

Jun 30, 2026

Jun 29, 2026

IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill

Jun 29, 2026

IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen - ChartMill

Jun 29, 2026

Jun 28, 2026

Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus

Jun 28, 2026

REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits

Jun 28, 2026

Jun 27, 2026

Why Is IOVA Stock Falling Today? - Stocktwits

Jun 27, 2026

Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView

Jun 27, 2026

Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join - The National Law Review

Jun 27, 2026

Why Iovance Biotherapeutics (IOVA) Is Up 7.7% After Australian Conditional OK For Amtagvi Cell Therapy - Sahm

Jun 27, 2026